UT Health San Antonio registers Phase 1/2 trial of Corcept's relacorilant in T2D with cortisol excesNov 9Trial updateCorcept Therapeuticsrelacorilant
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Corcept's miricorilant MASLD Phase 1 study completed, University of Missouri siteSep 30Trial updateCorcept Therapeuticsmiricorilant
Corcept's ROSELLA Phase 3 posts results for relacorilant plus nab-paclitaxel in ovarian cancerSep 25Trial updateCorcept Therapeuticspaclitaxel
Corcept names Justin Gunn to succeed retiring endocrinology president Sean MaduckSep 23PeopleCorcept Therapeutics
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarterJul 29Quarterly updateCorcept Therapeuticsmifepristone